

Publications auxquelles l'Aretasc a participé en 2016

- 1- DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer ; A secondary analysis of the PETACC 8 randomized clinical trial .
Boige V, Vincent M, Alexandre P : JAMA Oncol 2016 Jan 21. doi :10.1001
- 2- Prognostic effect of BRAF and KRAS Mutations in patients with stage III colon cancer treated with leucovorin fluorouracil and oxaliplatin with or without cetuximab A post hoc analysis of the PETACC-8 trial.
Taieb J, Zaanan A, Le Malicot K. JAMA Oncol 2016 Jan 15/14.1-11
- 3- Primary analysis of the EORTC 1004/BIG 3-04 Mindact study : A prospective, randomized study evaluating the clinical utility of the 70-gene signature (mammaPrint) combined with common clinical/pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.
M. Piccart, E. Rutgers S. Delage ; AACR , April 28, 2016
- 4- Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer. CRIG-005 randomized trial. Mcackett JR, Pienkowski T, Crown J
Ann Oncol (2016) V 27(6) :1041-1047 doi :10.1093/annonc/mdw 098.
- 5- Concomitant ou séquentiel pour le trastuzumab adjuvant : étude combinée de PHARE et SIGNAL : Esmo 2016 PivotX et al ; abstr 1440
- 6- Enquête PONDx en France ; » Enquête d'utilisation du test Oncotype DX en pratique clinique courante ». Courtit E, Bourgeois H, Laharie H, Vannetzel JM, Bonichon- Lamichhane N
- 7- Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
The Lancet Oncology [Volume 17, No. 6](#), p747–756, June 2016 : Carrie C, Hasbini A, Delaroche G